Abstract
The standard of care for cancer patients aims to eradicate the tumor by killing the maximum number of cancer cells using the maximum tolerated dose (MTD) of a drug. MTD causes significant toxicity and selects for resistant cells, eventually making the tumor refractory to treatment. Adaptive therapy aims to maximize time to progression (TTP), by maintaining sensitive cells to compete with resistant cells. We explored both dose modulation (DM) protocols and fixed dose (FD) interspersed with drug holiday protocols. In contrast to previous single drug protocols, we explored the determinants of success of two-drug adaptive therapy protocols, using an agent-based model. In almost all cases, DM protocols (but not FD protocols) increased TTP relative to MTD. DM protocols worked well when there was more competition, with a higher cost of resistance, greater cell turnover, and when crowded proliferating cells could replace their neighbors. The amount that the drug dose was changed, mattered less. The more sensitive the protocol was to tumor burden changes, the better. In general, protocols that used as little drug as possible, worked best. Preclinical experiments should test these predictions, especially dose modulation protocols, with the goal of generating successful clinical trials for greater cancer control.
Funding Information
  • NIH (U54 CA217376, U01CA23238, U2C CA233254, P01 CA91955, R01 CA140657, BC132057, ADHS18-198847)
  • CDMRP Breast Cancer Research (U54 CA217376, U01CA23238, U2C CA233254, P01 CA91955, R01 CA140657, BC132057, ADHS18-198847)
  • Arizona Biomedical Research Commission (U54 CA217376, U01CA23238, U2C CA233254, P01 CA91955, R01 CA140657, BC132057, ADHS18-198847)
  • Moffitt Cancer Center of Excellence for Evolutionary Therapy (U54 CA217376, U01CA23238, U2C CA233254, P01 CA91955, R01 CA140657, BC132057, ADHS18-198847)

This publication has 73 references indexed in Scilit: